Commercial Partnerships for VoiceMed Check Market Launch

VoiceMed is seeking commercial and strategic partners to support the market launch and scale-up of VoiceMed Check, our AI-powered solution for COPD case finding.

VoiceMed Check is designed to identify people at risk of COPD, particularly adults aged 40+ with a history of smoking or relevant occupational or environmental exposure, who may benefit from further clinical assessment and diagnostic confirmation.

Following CE marking as a Class IIa medical device, planned for 2027, our go-to-market strategy will focus initially on bringing VoiceMed Check to people at risk through GPs and pharmacies.

We are therefore looking to establish partnerships with pharmaceutical companies, pharmacy chains and networks, GP and primary care networks, healthcare providers, distributors, digital health platforms, and companies already providing products or services to pharmacies and primary care.

Potential collaborations can include distribution and commercialization, integration into existing digital platforms, activation of GP or pharmacy networks, COPD awareness and case-finding initiatives, and country-specific market-entry projects.

For pharmaceutical companies, VoiceMed Check can support initiatives aimed at improving COPD case finding and helping more at-risk individuals enter an appropriate diagnostic pathway. For pharmacy and GP partners, the solution offers a scalable digital tool that requires only a smartphone and can be incorporated into existing patient interactions and respiratory health initiatives.

We are particularly interested in partners with established access to GPs, pharmacies or populations at risk of COPD who can work with VoiceMed to bring the solution into real-world healthcare pathways and support its adoption across European markets.